Although previous clinical trials suggest that SGLT2 inhibitors have a neutral effect on stroke [6], the HR was 1.18 (95% CI 0.94–1.48) in those under 65 years of age and 0.83 (95% CI 0.69–1.00) in those aged 65 years or older (pinteraction = 0.02), suggesting a different efficacy on stroke between older and younger patients. The gene discussed is SLC5A2; the disease is Stroke.